Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drugdrug interactions

Xenobiotica

Volumn 40, Issue 7, 2010, Pages 467-475

  Gao, Yiwen ^a   Liu, Duan ^a   Wang, Huijuan ^a   Zhu, Juanli ^a   Chen, Chao ^a  

^a NORTHWEST UNIVERSITY   (China)

Author keywords

CYP2C8; Genetic polymorphisms; Genotype dependent drugdrug interactions; Polymorphic activity

Indexed keywords

CYTOCHROME P450 2C8; NIFEDIPINE; PACLITAXEL; QUERCETIN; RALOXIFENE; TRANYLCYPROMINE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CHROMAN DERIVATIVE; CYP2C8 PROTEIN, HUMAN; ISOENZYME; PRIMER DNA; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG INHIBITION; ENZYME INHIBITION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROLOGOUS EXPRESSION; HYDROXYLATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MICHAELIS MENTEN KINETICS; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; YEAST; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG DEVELOPMENT; DRUG INTERACTION; GENE VECTOR; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KINETICS; METABOLISM; MICROSOME; REGRESSION ANALYSIS; SACCHAROMYCES CEREVISIAE;

ARYL HYDROCARBON HYDROXYLASES; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2C8; DNA PRIMERS; DRUG DISCOVERY; DRUG INTERACTIONS; GENETIC VECTORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES; NIFEDIPINE; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; RALOXIFENE; REGRESSION ANALYSIS; SACCHAROMYCES CEREVISIAE; THIAZOLIDINEDIONES;

EID: 77953594273     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.487163     Document Type: Article

References (33)

1. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. (2002). Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691
2. Bahadur N, Leathart JB, Mutch E, Stermel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579-1589
3. Baldwin SJ, Clarke SE, Chenery RJ. (1999). Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48:424-432
4. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye-binding. Anal Biochem 72:248-254
5. Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. (2003). Drug interaction of paclitaxel metabolism in human liver microsomes. J Chemotherapy 3:266-274
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597-607.
7. Goldstein JA. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349-355
8. Guidance for Industry (2006). Drug interaction studies-study design, data analysis, and implications for dosing and labeling. Available at: http://www.fda.gov/cder/guidance/6695dft.pdf. Accessed on March 14, 2006.
9. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The pharmacological basis of therapeutics. New York, USA: McGraw-Hill Professional.
10. Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suauki S, Satoh T, Shinoda S, Kataoka H, Narimatsu S. (2002). Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem Pharmacol 64:1101-1110
11. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoch M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. (2005). Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K274R, and K383N, found in a Japanese population. Drug Metab Dispos 33:630-636
12. Ho SN, Hunt HD, Horton RM, Pullen JK, Peras LR. (1989). Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77:51-59
13. Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher C, Rettie AE, Tracy TS. (2005). CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68:644-654
14. Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in-vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486
15. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. (2002). Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci 4:53-60.
16. Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharma Res 17:336-343
17. Krippendorff BF, Lienau P, Reichel A, Huisinga W. (2007) Optimizing classification of drug-drug interaction potential for CYP450 iso-enzymes inhibition assays in early drug discovery. J Biomol Screen 12:92-99
18. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. (2006). CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-1975
19. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. (1999). Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104.
20. Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, Mansuy D. (2004). Analysis of human cytochrome P450 2C8 substrate specific using a substrate pharmacophore and site-direct mutants. Biochemistry 43:15379-15392
21. Muthiah YD, Lee WL, The LK, Ong CE, Ismail R. (2005). Genetics polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J Clin Pharm Ther 30:487-490
22. Niemi M, Backman JT, Granfors JL, Laitila J, Neuvonen M, Neuvonen PJ. (2003a). Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46:1319-1323 (Pubitemid 37297200)
23. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. (2003b). Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 74:347-351
24. Omura T, Sato R. (1964). Carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378
25. Pearce RE, Vakkalagadda GR, Leeder JS. (2002). Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochrome P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab Dispos 30:1170-1179
26. Projean D, Morin PE, Tu TM, Ducharme J. (2003). Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 33:841-854
27. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. (1994). Selective biotransformation of taxol to 6-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546
28. Singh R, Ting JG, Pan Y, The LK, Ismail R, Ong CE. (2008). Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23: 165-174
29. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. (1995). Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566-575
30. Totah RA, Rettie AE. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352
31. Tuker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Br J Clin Pharmacol 70:103-114
32. Walsky RL, Gaman EA, Obach RT. (2005). Examination of 209 drugs for inhibition of cytochrome P4502C8. J Clin Pharmacol 45: 68-78.
33. Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. (2000). In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica 30:61-70.